Financials data is unavailable for this security.
View more
Year on year Qingdao Vland Biotech INC grew revenues 3.07% from 1.16bn to 1.20bn while net income improved 15.56% from 69.84m to 80.71m.
| Gross margin | 45.41% |
|---|---|
| Net profit margin | 8.57% |
| Operating margin | 10.57% |
| Return on assets | 3.70% |
|---|---|
| Return on equity | 4.66% |
| Return on investment | 5.78% |
More ▼
Cash flow in CNYView more
In 2023, Qingdao Vland Biotech INC increased its cash reserves by 6.75%, or 14.03m. Cash Flow from Financing totalled 156.36m or 13.04% of revenues. In addition the company generated 153.59m in cash from operations while cash used for investing totalled 296.66m.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 6.77 |
|---|---|
| Tangible book value per share | 5.91 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.07 |
|---|---|
| Quick ratio | 0.8687 |
| Total debt/total equity | 0.4874 |
|---|---|
| Total debt/total capital | 0.3127 |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 14.29%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.79% |
|---|---|
| Div growth rate (5 year) | -6.89% |
| Payout ratio (TTM) | 32.20% |
| EPS growth(5 years) | -9.02 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 21.24 |
More ▼
